论文部分内容阅读
目的观察阿德福韦酯抗乙型肝炎病毒所致肝纤维化的临床疗效。方法将134例慢性乙肝患者随机分为A、B组,A组给予阿德福韦酯及基础保肝治疗,B组给予基础保肝治疗加复方丹参治疗,均治疗12周。观察治疗前、后2组血清玻璃酸酶、层粘连蛋白、Ⅲ期前胶原肽、Ⅳ型胶原的变化。结果治疗后A组4项指标与B组相比均明显降低,差异有统计学意义(P<0.05)。结论阿德福韦酯是治疗乙型肝炎病毒所致肝纤维化有效药物之一。
Objective To observe the clinical efficacy of adefovir dipivoxil against hepatitis B virus induced liver fibrosis. Methods A total of 134 patients with chronic hepatitis B were randomly divided into A and B groups. A group was treated with adefovir dipivoxil and basic hepatoprotective therapy. Group B was given basic hepatoprotective therapy plus salvia miltiorrhiza complex treatment for 12 weeks. Changes of serum hyaluronan, laminin, stage Ⅲ procollagen peptide and type Ⅳ collagen in the two groups before and after treatment were observed. Results After treatment, the four indexes in group A were significantly lower than those in group B, the difference was statistically significant (P <0.05). Conclusion Adefovir dipivoxil is one of the effective drugs for treating hepatic fibrosis induced by hepatitis B virus.